Everest Medicines

Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis

by

SHANGHAI, Sept. 19, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines in Greater China and other parts of Asia, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for cefepime-taniborbactam … Read more

Everest Medicines’ Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association

by

SHANGHAI, June 20, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) made presentations on data from the NeflgArd Phase 3 Study at the European Renal Association – European Dialysis and Transplant Association Congress (ERA-EDTA), which was held in … Read more

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer

by

SHANGHAI, June 15, 2023 /PRNewswire/ — Everest Medicines (HKEX: 1952.HK, “Everest,” or the “Company”), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr. Mike Berry has been appointed Chief Technology Officer, effective immediately. He has more than 30 years of industrial experience in advancing projects from pre-clinical … Read more

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

by

SHANGHAI, May 16, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-severe active ulcerative colitis … Read more

Nefecon Included in the Reimbursement Drug List of “Beijing Puhui Health Insurance Program” as a First-in-Disease Therapy for IgA Nephropathy

by

SHANGHAI, May 11, 2023 /PRNewswire/ — An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the “Beijing Puhui Health Insurance Program.” Nefecon is a first-in-disease treatment for adults with primary immunoglobulin A nephropathy (IgAN). Nefecon has been approved by the United States Food … Read more